Article
Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: study by the Nagasaki CML Study Group.
Leukemia research - 1 Jan 2014
Itonaga Hidehiro, Tsushima Hideki, Imanishi Daisuke, Hata Tomoko, Doi Yuko, Mori Sayaka, Sasaki Daisuke, Hasegawa Hiroo, Matsuo Emi, Nakashima Jun, Kato Takeharu, Horai Makiko, Taguchi Masataka, Matsuo Masatoshi, Taniguchi Hiroaki, Makiyama Junnya, Sato Shinya, Horio Kensuke, Ando Koji, Moriwaki Yuji, Sawayama Yasushi, Ogawa Daisuke, Yamasaki Reishi, Takasaki Yumi, Imaizumi Yoshitaka, Taguchi Jun, Kawaguchi Yasuhisa, Yoshida Shinichiro, Joh Tatsuro, Moriuchi Yukiyoshi, Nonaka Hiroaki, Soda Hisashi, Fukushima Takuya, Nagai Kazuhiro, Kamihira Shimeru, Tomonaga Masao, Yanagihara Katsunori, Miyazaki Yasushi
Abstract excerpt
An appropriate trigger for BCR-ABL1 mutation analysis has not yet been established in unselected cohorts of chronic-phase chronic myelogenous leukemia patients. We examined 92 patients after 12 months of tyrosine kinase inhibitor (TKI) treatment in Nagasaki Prefecture, Japan. Univariate analysis revealed that significant factors associated with not attaining a major molecular response (MMR) were the presence of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.